ASCO 2021

In the phase 2 NANT2011-01 trial, levels of circulating tumor DNA (ctDNA) were evaluated during treatment. In patients with a clinical response, ctDNA becomes undetectable over time. Neuroblastoma is the most common extracranial...

First results from the phase 3 PEACE-1 trial show that adding abiraterone to androgen deprivation therapy (ADT) plus docetaxel significantly improves progression-free survival in patients who present with de novo metastatic...

First results of the phase 3 RELATIVITY-047 trial validate the efficacy of dual checkpoint blockade demonstrated with the LAG-3 inhibitor relatlimab and nivolumab in patients with advanced melanoma.  Lymphocyte-activation gene 3...

An exploratory post-hoc pooled analysis of three phase 3 trials with atezolizumab in patients with stage IV non-small cell lung cancer (NSCLC) – IMpower130, IMpower132, and IMpower150 – shows longer overall survival for patients...

After initial results over 5 years ago, long-term follow-up data from 3 clinical trials – CheckMate 067, COLUMBUS, and ABC – show a durable and sustained clinical benefit for patients with melanoma. In the phase 3 CheckMate 067...

First-line treatment of patients with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) with pembrolizumab improves overall survival, but the prespecified threshold for...

First results of the phase 3 KEYNOTE 564 trial show that adjuvant therapy with pembrolizumab after nephrectomy enhances disease-free survival of patients treated for locoregional clear cell renal cell cancer (RCC). Nephrectomy...

First results of the randomized, phase 3 CheckMate 648 study demonstrate superior overall survival of first-line treatment with nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy alone. Standard...

Addition of 177Lu-PSMA-617 therapy to standard of care for patients with metastatic castration-resistant prostate cancer (mCRPC) significantly improves survival, according to results from the randomized, phase 3 VISION trial....

RBN-2397 is a potent, selective inhibitor of PARP7 that could potentially release the brake on the antitumor immunity, is well tolerated, and demonstrated proof of mechanism in a first-in-human trial. Targeting cytosolic nucleic...